超声引导射频消融与甲状腺腺叶切除术治疗低危甲状腺微小乳头状癌的倾向匹配队列研究
该回顾性队列研究纳入884例单发低危甲状腺微小乳头状癌患者,经倾向评分匹配后比较射频消融(RFA)与甲状腺腺叶切除术(TL)各332例。中位随访48.3个月,两组局部进展、淋巴结转移、复发及4年无复发生存率无显著差异;RFA组手术时间、出血量、住院时间、费用及并发症率均更低。
要点
- 低危PTMC患者RFA与TL的4年肿瘤学结局无显著差异。
- RFA组并发症率0% vs TL组4.5%,且手术时间和住院更短。
- RFA可作为低危PTMC现有治疗选择的有前景替代方案。
核心结论
- 对于低危PTMC,RFA与TL的四年临床结局相当,RFA可能是有前景的微创替代选择。
研究设计与样本
- 回顾性队列研究,纳入2014年6月至2018年3月884例单发低危PTMC患者,其中TL组460例、RFA组424例。
- 采用倾向评分匹配后,TL组和RFA组各332例,TL组平均年龄43.8±9.5岁,RFA组44.1±9.5岁。
主要发现
- 中位随访48.3(四分位距23.2)个月,TL组与RFA组局部肿瘤进展分别为1.8% vs 3.3%(p=0.209)。
- 淋巴结转移0.6% vs 0.6%(p=1.000),复发PTMC 1.2% vs 2.4%(p=0.244),持续病灶0% vs 0.3%(p=0.317)。
- 4年无复发生存率98.2% vs 97.0%(p=0.223),未检测到远处转移,RFA组无患者转为延迟手术。
- RFA组手术时间3.4(2.5)vs 86.0(37.0)分钟、估计出血量0 vs 20(10.0)mL、住院0 vs 7.0(3.0)天、费用2035.7(254.0)vs 2269.1(943.4)美元、并发症率0% vs 4.5%,均p<0.001。
- Cox分析显示治疗方式与复发关联仍不显著(p=0.247)。
临床怎么用
- 对于拒绝手术或主动监测的低危PTMC患者,RFA可作为一种微创治疗选择。
- RFA具有手术时间短、出血少、住院短、费用低及并发症少的优势。
局限性
- 本研究为回顾性研究,可能存在选择偏倚。
- 随访时间中位48.3个月,长期结局仍需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Thermal ablation (TA) has been applied in patients with low-risk papillary thyroid microcarcinoma (PTMC) who refuse surgery or active surveillance (AS). Recently, TA has been proposed as a potential therapeutic option for patients who are suitable for surgery or AS. However, the clinical outcomes of TA versus surgery remains controversial because of a lack of sufficient data. This study aimed to compare the clinical outcomes between radiofrequency ablation (RFA) versus thyroid lobectomy (TL) for low-risk PTMC in a large cohort. Methods: This retrospective study evaluated 884 patients with unifocal low-risk PTMC treated with TL or RFA from June 2014 to March 2018. Among them, 460 patients underwent TL (TL group) and 424 patients, who refused surgery or AS, underwent RFA (RFA group). Patients were regularly followed up after treatment. Local tumor progression, recurrence-free survival (RFS), complications, and treatment variables, including procedure time, estimated blood loss, hospitalization, and cost, were compared after propensity score matching (PSM). Results: After PSM, a total of 332 patients underwent TL (mean ages 43.8 ± 9.5 years) and 332 underwent RFA (mean ages 44.1 ± 9.5 years). During the follow-up (median [interquartile ranges], 48.3 [23.2] months), no significant differences were observed in local tumor progression (1.8% vs. 3.3%, p = 0.209), lymph node metastasis (0.6% vs. 0.6%, p = 1.000), recurrent PTMC (1.2% vs. 2.4%, p = 0.244), persistent lesion (0% vs. 0.3%, p = 0.317), and 4-year RFS rates (98.2% vs. 97.0%, p = 0.223) between the TL and RFA groups. Distant metastasis was not detected. None of the patients who were treated by RFA underwent delayed surgery. Patients undergoing RFA had shorter procedure time (3.4 [2.5] vs. 86.0 [37.0] minutes, p < 0.001), lower estimated blood loss (0 vs. 20 [10.0] mL, p < 0.001), shorter hospitalization (0 vs. 7.0 [3.0] days, p < 0.001), lower cost ($2035.7 [254.0] vs. $2269.1 [943.4], p < 0.001) and lower complication rate (0% vs. 4.5%, p < 0.001) than those treated by TL. The association between treatment modality and recurrence remained nonsignificant after Cox analysis (p = 0.247). Conclusions: This large matched study revealed comparable four-year clinical outcomes between RFA and TL for low-risk PTMC. As a minimally invasive modality, RFA may be a promising alternative to the existing treatment options for low-risk PTMC.
引用
- Yan L, Zhang M, Song Q, et al. Ultrasound-Guided Radiofrequency Ablation Versus Thyroid Lobectomy for Low-Risk Papillary Thyroid Microcarcinoma: A Propensity-Matched Cohort Study of 884 Patients. Thyroid. 2021. PMID: 34269611. doi:10.1089/thy.2021.0100
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。